Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.

Biotechnology

Olema Oncology

Sean P. Bohen

Kristin Lowland Lanzi

Peter Kushner

Geoffrey Mogilner

Sasha Austin

Kamesh Kuchimanchi

Jim Zhang

Kristin Lanzi

David C. Myles

Naseem Zojwalla

Julie Dexter

Shane Kovacs

The Leadership Team at Olema Oncology is responsible for steering the strategic vision and operational execution of the company’s mission to develop innovative treatments for women’s cancers. Comprising senior executives from diverse areas such as clinical development, pharmacology, and operations, the team collaborates to advance clinical trials, optimize resource allocation, and foster a culture of innovation and excellence. Their collective expertise is pivotal in guiding Olema through the complexities of drug development and bringing transformative therapies like OP-1250 to market.

Leadership Team

Clinical Development Team

Clinical and Pharmacology

Leadership Team

About

Team members

Other teams at Olema Oncology

Clinical Development Team

Clinical and Pharmacology